Vaxart (OTCMKTS:VXRT) Share Price Crosses Below Two Hundred Day Moving Average – What’s Next?

Vaxart, Inc. (OTCMKTS:VXRT) passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.61 and traded as low as $0.58. Vaxart shares last traded at $0.61, with a volume of 200,011 shares changing hands.

Vaxart Stock Performance

The stock has a 50 day moving average of $0.64 and a two-hundred day moving average of $0.61. The firm has a market capitalization of $148.13 million, a P/E ratio of 4.07 and a beta of 1.10.

Vaxart (OTCMKTS:VXRT) last announced its earnings results on Thursday, May 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.02. The firm had revenue of $39.23 million during the quarter, compared to analysts’ expectations of $50.50 million. Vaxart had a return on equity of 61.43% and a net margin of 14.51%.

Institutional Trading of Vaxart

Several large investors have recently modified their holdings of the company. Goldman Sachs Group Inc. acquired a new position in Vaxart in the 1st quarter valued at $31,000. Creative Planning acquired a new position in Vaxart during the 2nd quarter worth $33,000. Invesco Ltd. lifted its position in Vaxart by 93.1% during the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 70,568 shares during the last quarter. Raymond James Financial Inc. boosted its holdings in Vaxart by 16.9% during the second quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock valued at $107,000 after acquiring an additional 34,075 shares during the period. Finally, Jones Financial Companies Lllp boosted its holdings in Vaxart by 276,364.7% during the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock valued at $196,000 after acquiring an additional 478,111 shares during the period. 18.05% of the stock is owned by institutional investors.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.